- Home
- AMGN
AMGN
Amgen Inc.
as 07-26-2024 4:00pm EST
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 164.4B | IPO Year: | N/A |
| Target Price: | $312.22 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.01 | EPS Growth: | -52.35 |
| 52 Week Low/High: | $228.21 - $346.85 | Next Earning Date: | 08-06-2024 |
| Revenue: | $29,532,000,000 | Revenue Growth: | 12.76% |
| Revenue Growth (this year): | 19.4% | Revenue Growth (next year): | 2.84% |
Stock Insider Trading Activity of Amgen Inc. (AMGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | AMGN | SVP & CCO | May 3 '24 | Sell | $313.09 | 2,117 | $662,801.58 | 9,883 | SEC Form 4 |
| Grygiel Nancy A. | AMGN | SVP & CCO | Dec 4 '23 | Sell | $273.03 | 2,096 | $572,275.70 | 10,874 | SEC Form 4 |
| Graham Jonathan P | AMGN | EVP, Gen. Counsel & Secy. | Nov 8 '23 | Sell | $272.81 | 10,000 | $2,728,136.00 | 28,078 | SEC Form 4 |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Amgen (AMGN) Stock Moves -0.39%: What You Should Know
Investor's Business Daily
a day ago
Amgen Surges As Weight-Loss Trials Drive Excitement
Zacks
2 days ago
What Lies in Store for Healthcare ETFs in Q2 Earnings?
Zacks
3 days ago
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Simply Wall St.
4 days ago
Investors in Amgen (NASDAQ:AMGN) have seen splendid returns of 122% over the past five years
Medical Device Network
4 days ago
Nanotechnology in medicine: Who are the leading public companies?
Investor's Business Daily
4 days ago
Dow Jones Leader Amgen, Nvidia Stock, Coinbase In Or Near Buy Zones
Zacks
4 days ago
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
Compare AMGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.